Spyre Therapeutics To Report SPY001 Part A Induction Topline Results For Ulcerative Colitis Patients On April 13

Benzinga Newsdesk www.benzinga.com Neutral 93.6%

Neg 0% Neu 93.6% Pos 0%

Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results.